Biodel has registered an IPO aimed at raising $86.2 million. The company is developing therapies for endocrine diseases such as diabetes and osteoporosis. Most of the money raised is earmarked for R&D.
NeurogesX has filed with the SEC to raise up to $69 million in an IPO. Dr. Wendye Robbins helped found the company in 2000, setting out to develop new therapies for neuropathc pain. NGX-4010 hit its primary endpoint for a Phase III trial last October. NGX-1991 is in Phase I, according to the company's Web site.